ବ୍ୟବହାରକାରୀ:Doc James/Test
Clinical data | |
---|---|
Pronunciation | /pæˈzoʊpənɪb/ paz-OH-pə-nib |
Trade names | Votrient |
AHFS/Drugs.com | monograph |
MedlinePlus | a610013 |
data | |
Pregnancy category | |
Routes of administration | By mouth (tablets) |
Drug class | Tyrosine kinase inhibitor[୧] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 21% (14–39%)[୩] |
Protein binding | >99.5%[୩][୨] |
Metabolism | Liver: CYP3A4 (major), 1A2 and 2C8 (minor)[୨] |
Elimination half-life | 30.9±4 hours[୩] |
Excretion | Faeces (primary), urine (<4%)[୨] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C21H23N7O2S |
Molar mass | ୪୩୭.୫୨ g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Pazopanib, sold under the brand name Votrient, is a medication used to treat renal cell carcinoma (RCC) and certain soft tissue sarcoma.[୪] In RCC it is used when other treatments have failed.[୪] It is taken by mouth.[୪]
Common side effects include diarrhea, high blood pressure, white hair, nausea, tiredness, abdominal pain, low blood cells, and liver problems.[୧] Other side effects may include low thyroid, QT prolongation, bleeding, blood clots, and gastrointestinal perforation.[୧] Use during pregnancy may harm the baby.[୧] It is a tyrosine kinase inhibitor.[୧]
Pazopanib was approved for medical use in the United States in 2009.[୧] In Europe it received conditional approval in 2010 and full approval in 2013.[୫] In the United Kingdom it costs the NHS about £2,250 per month as of 2021.[୪] In the United States this amount costs about 14,200 USD.[୬]
References
[ସମ୍ପାଦନା]- ↑ ୧.୦ ୧.୧ ୧.୨ ୧.୩ ୧.୪ ୧.୫ ୧.୬ "PAZOPanib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 26 October 2021.
- ↑ ୨.୦ ୨.୧ ୨.୨ "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 2 February 2014. Retrieved 27 January 2014.
- ↑ ୩.୦ ୩.୧ ୩.୨ "CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Archived (PDF) from the original on 9 October 2016. Retrieved 8 October 2016.
- ↑ ୪.୦ ୪.୧ ୪.୨ ୪.୩ ୪.୪ ୪.୫ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1039. ISBN 978-0857114105.
- ↑ "Votrient". Archived from the original on 22 October 2021. Retrieved 26 October 2021.
- ↑ "Pazopanib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 26 October 2021.